At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 352 enrolled
Drug / intervention
Laquinimod +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/Day) as Treatment in Patients With Huntington's Disease
Teva Branded Pharmaceutical Products R&D, Inc.·interventional·Posted Aug 13, 2014·Updated May 4, 2020
In Brief
A Phase 2 clinical trial evaluating Laquinimod and Placebo for Huntington's Disease. Completed, enrolled 352 participants across 53 sites in 10 countries.
Detailed Summary
The primary objective of this study is to assess the efficacy of laquinimod as treatment in participants with HD after 52 weeks using the Unified Huntington's Disease Rating Scale Total Motor Score (UHDRS-TMS or TMS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuntington's Disease
CountriesCanada, Czechia, Germany, Italy, Netherlands, Portugal, Russia, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 2014
Enrollment StartOct 2014
Primary CompletionJun 2018
TodayJul 2026
First PostedAug 13, 2014
Enrollment StartOct 28, 2014
Primary CompletionJun 19, 2018
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 11.9 years ago
Interventions
Laquinimoddrug
Laquinimod capsules will be administered as per the dose and schedule specified in the respective arms.
Placebodrug
Matching laquinimod placebo will be administered as per the schedule specified in the respective arms.